These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38554171)

  • 1. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
    Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
    Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
    Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
    Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.
    Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y
    Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs.
    Ozer Y; Yildiz M; Turan H; Tarcin G; Bingol Aydin D; Gunalp A; Haslak F; Kilic Konte E; Aslan E; Koker O; Bayramoglu E; Sahin S; Adrovic A; Barut K; Kasapcopur O; Evliyaoglu O
    Clin Rheumatol; 2024 Jan; 43(1):399-406. PubMed ID: 37646858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate for juvenile idiopathic arthritis.
    Tan J; Renton WD; Whittle SL; Takken T; Johnston RV; Tiller G; Munro J; Buchbinder R
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD003129. PubMed ID: 38334147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
    Raab A; Kallinich T; Huscher D; Foeldvari I; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner JB; Klein A; Horneff G
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):41. PubMed ID: 33752685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids.
    Brik R; Gepstein V; Berkovitz D
    Clin Rheumatol; 2005 Nov; 24(6):612-4. PubMed ID: 15877178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
    Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S
    Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What to Expect When Systemic Treatment in Juvenile Idiopathic Arthritis Is Withdrawn?
    Nieto-González JC; Garulo DC; Boteanu A; Trives-Folguera L; García-Fernández A; Navarro PG; Robledillo JCL; Monteagudo-Saéz I
    J Rheumatol; 2023 Oct; 50(10):1326-1332. PubMed ID: 37527855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score.
    Horneff G; Becker I
    Rheumatology (Oxford); 2014 Jul; 53(7):1229-34. PubMed ID: 24599918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Satisfaction With and Adherence to Disease-Modifying Antirheumatic Drugs in Adult Patients With Juvenile Idiopathic Arthritis.
    Tollisen A; Flatø B; Selvaag AM; Aasland A; Ingebrigtsen T; Sagen J; Lerdal A
    Arthritis Care Res (Hoboken); 2021 Feb; 73(2):221-231. PubMed ID: 31758669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
    Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
    Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial.
    van Dijk BT; Bergstra SA; van den Berg JM; Schonenberg-Meinema D; van Suijlekom-Smit LWA; van Rossum MAJ; Koopman-Keemink Y; Ten Cate R; Allaart CF; Brinkman DMC; Hissink Muller PCE
    Pediatr Rheumatol Online J; 2024 May; 22(1):53. PubMed ID: 38730442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
    Klotsche J; Minden K; Niewerth M; Horneff G
    Ann Rheum Dis; 2018 Jul; 77(7):996-1002. PubMed ID: 29453217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
    Klein A; Becker I; Minden K; Foeldvari I; Haas JP; Horneff G
    Scand J Rheumatol; 2019 Mar; 48(2):95-104. PubMed ID: 30411654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leflunomide treatment in juvenile idiopathic arthritis.
    Ayaz NA; Karadağ ŞG; Çakmak F; Çakan M; Tanatar A; Sönmez HE
    Rheumatol Int; 2019 Sep; 39(9):1615-1619. PubMed ID: 31327053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of methotrexate in children with rheumatic diseases.
    Gutiérrez-Suárez R; Burgos-Vargas R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.